Literature DB >> 12230275

The relation of mutant p53 accumulation in transitional cell carcinoma of bladder with pathological stage, grade, recurrence and survival.

C O Yeniyol1, T Süelözgen, E Vardar, S Sural, H Postaci, A R Ayder.   

Abstract

In this study prognostic significance and clinical value of mutant p53 gene in bladder transitional cell tumors is investigated. In our clinic, between 1997-2000, transurethral resection was performed in 48 cases, 3 females (6%) and 45 males (94%) with the diagnosis of primary bladder tumor, age ranges between 30-81 years old (average 58.9 +/- 9.9). The patients whose pathology results were transitional cell carcinoma were gathered into two groups as p53 positive and p53 negative by immunohistochemical study. These cases who were followed 1-36 months were compared to each other for pathologic state, tumor grade, recurrence and survival. It's found out that mutant p53 accumulation is related to high grade and pathologic stage tumors. But it's concluded that p53 positivity doesn't effect recurrence and survival rates.

Entities:  

Mesh:

Year:  2001        PMID: 12230275     DOI: 10.1023/a:1019559121580

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  12 in total

1.  Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer.

Authors:  C J Logothetis; H J Xu; J Y Ro; S X Hu; A Sahin; N Ordonez; W F Benedict
Journal:  J Natl Cancer Inst       Date:  1992-08-19       Impact factor: 13.506

2.  Molecular genetic alterations in superficial and locally advanced human bladder cancer.

Authors:  J C Presti; V E Reuter; T Galan; W R Fair; C Cordon-Cardo
Journal:  Cancer Res       Date:  1991-10-01       Impact factor: 12.701

Review 3.  Clinical implications of the p53 tumor-suppressor gene.

Authors:  C C Harris; M Hollstein
Journal:  N Engl J Med       Date:  1993-10-28       Impact factor: 91.245

4.  Identification of p53 gene mutations in bladder cancers and urine samples.

Authors:  D Sidransky; A Von Eschenbach; Y C Tsai; P Jones; I Summerhayes; F Marshall; M Paul; P Green; S R Hamilton; P Frost
Journal:  Science       Date:  1991-05-03       Impact factor: 47.728

5.  Expression of p53 product in Chinese human bladder carcinoma.

Authors:  D W Ye; J F Zheng; S X Qian; Y J Ma
Journal:  Urol Res       Date:  1993-05

6.  Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC.

Authors:  A S Sarkis; D F Bajorin; V E Reuter; H W Herr; G Netto; Z F Zhang; P K Schultz; C Cordon-Cardo; H I Scher
Journal:  J Clin Oncol       Date:  1995-06       Impact factor: 44.544

7.  Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer.

Authors:  Y C Tsai; P W Nichols; A L Hiti; Z Williams; D G Skinner; P A Jones
Journal:  Cancer Res       Date:  1990-01-01       Impact factor: 12.701

8.  Preliminary mapping of the deleted region of chromosome 9 in bladder cancer.

Authors:  P Cairns; M E Shaw; M A Knowles
Journal:  Cancer Res       Date:  1993-03-15       Impact factor: 12.701

Review 9.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

10.  p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.

Authors:  D Esrig; C H Spruck; P W Nichols; B Chaiwun; K Steven; S Groshen; S C Chen; D G Skinner; P A Jones; R J Cote
Journal:  Am J Pathol       Date:  1993-11       Impact factor: 4.307

View more
  1 in total

1.  Cell-cycle control in urothelial carcinoma: large-scale tissue array analysis of tumor tissue from Maine and Vermont.

Authors:  Petra Lenz; Ruth Pfeiffer; Dalsu Baris; Alan R Schned; Mikiko Takikita; M Cristina Poscablo; Molly Schwenn; Alison Johnson; Michael Jones; Masatoshi Kida; Kenneth P Cantor; Nathaniel Rothman; Debra T Silverman; Stephen M Hewitt; Lee E Moore
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-07-03       Impact factor: 4.254

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.